FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Vashington,	D.C. 20549
-------------	------------

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average bu	ırden								
houre per reenonee.	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person HEDRICK MARC H					2. Issuer Name and Ticker or Trading Symbol PLUS THERAPEUTICS, INC. [PSTV]								(Che	Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last)	,	irst) PEUTICS INC.	(Middle)			. Date of Earliest Transaction (Month/Day/Year) 15/08/2024							X	below)	(give title nief Exec	Other (s below) Officer	pecify		
4200 MARATHON BOULEVARD, SUITE 200				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) AUSTIN	T	X	78756										Χ	Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(S	tate)	(Zip)		R	Rule 10b5-1(c) Transaction Indication													
	Check this box to indicate that a transaction was made pursuant to the affirmative defense conditions of Rule 10b5-1(c). See Instruction																		
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
Dat			Date			2A. Deemed Execution Date, if any (Month/Day/Year		, Transaction D Code (Instr. 5)		Dispose	Securities Acquired (A) sposed Of (D) (Instr. 3, 4			5. Amoun Securities Beneficia Owned Fo	s Form ally (D) o ollowing (I) (In		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
								Code	v	Amount		(A) or (D)	Price	Transacti (Instr. 3 a	ion(s)			(IIIStr. 4)	
Common Stock			05/08	5/08/2024				P		12,2:	12,255 A		\$2.04	12,425			D		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security (Instr. 3) 3. Transaction Date (Month/Day/Year) (Month/Day/Year) (Month/Day/Year)			ate, T	Code (Instr.		of		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amou of Securities Underlying Derivative Securi (Instr. 3 and 4)		curity	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				c	Code	v	(A)	(D)	Date Exercisa		xpiration ate	Title		Amount or Number of Shares					
Warrants (Right to buy)	\$1.79	05/08/2024			A		24,510		05/08/20	24	(1)			24,510	\$0	24,51	0	D	

Explanation of Responses:

- 1. The expiration date for 12,255 of the warrants (Series A warrants) is May 8, 2029. The expiration date for the other 12,255 warrants (Series B warrants) is the one-year anniversary of the effectiveness of a registration statement covering the resale of shares of common stock underlying the Series B warrants.
- 2. Half of the warrants are Series A warrants and the other half are Series B warrants.

/s/ Andrew Sims, attorney-in-05/10/2024 fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.